Skip to main content
. 2021 Feb 10;95(5):e02214-20. doi: 10.1128/JVI.02214-20

FIG 1.

FIG 1

Galectin-9 (Gal-9) reactivates latent HIV-1 in Jurkat-LAT-GFP cells. Bars show HIV-1 reactivation, calculated as percent GFP expression. After Gal-9 (2 nM) treatment (18 h) in a model of Jurkat-LAT-GFP cells (n = 4), we did not observe significant differences compared with the PMA (positive control). Similar results were obtained with the combination of Gal-9 (2 nM) with an antibody against TIM-3 (anti-TIM-3) (5 μg/ml). Significant differences were observed when we compared the Gal-9 reactivation alone or with anti-TIM-3 to the negative control (uninfected primary Jurkat cell line). Uninfected Jurkat cells that expressed GFP constitutively (Control GFP+) showed significantly higher GFP values than reactivation mediated by Gal-9. An increase (not significant) in GFP expression was observed after Gal-9 treatment compared to expression without Gal-9 addition (Jurkat cells). The same comparison achieved a significant difference when anti-TIM-3 was added (Gal-9 2 nM+ αTIM3 5 μg/ml). Statistical significance was calculated using the Mann-Whitney U test. P values of <0.05 were considered statistically significant. *, P < 0.05; NS, not significant.